N

Nanjing Vazyme Biotech Co Ltd
SSE:688105

Watchlist Manager
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Watchlist
Price: 23.5 CNY -6.67% Market Closed
Market Cap: 9.4B CNY
Have any thoughts about
Nanjing Vazyme Biotech Co Ltd?
Write Note

Nanjing Vazyme Biotech Co Ltd
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nanjing Vazyme Biotech Co Ltd
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
N
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Total Liabilities
ÂĄ1.7B
CAGR 3-Years
83%
CAGR 5-Years
83%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Liabilities
ÂĄ16B
CAGR 3-Years
13%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Liabilities
ÂĄ3B
CAGR 3-Years
47%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Total Liabilities
ÂĄ1.6B
CAGR 3-Years
27%
CAGR 5-Years
35%
CAGR 10-Years
12%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Liabilities
ÂĄ23.3B
CAGR 3-Years
32%
CAGR 5-Years
39%
CAGR 10-Years
62%
Imeik Technology Development Co Ltd
SZSE:300896
Total Liabilities
ÂĄ504.4m
CAGR 3-Years
72%
CAGR 5-Years
51%
CAGR 10-Years
N/A
No Stocks Found

Nanjing Vazyme Biotech Co Ltd
Glance View

Market Cap
9.3B CNY
Industry
Biotechnology

Nanjing Vazyme Biotech Co., Ltd. engages in the research and development, and production of antibody drugs. The company is headquartered in Nanjing, Jiangsu and currently employs 1,409 full-time employees. The company went IPO on 2021-11-15. The firm's main business is the technology research and development and product development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. The firm's products include polymerase chain reaction (PCR), reverse transcription, gene sequencing series and other biological reagent products, quantum dot immunofluorescence reagents, latex enhanced immune turbidity reagents and colloidal gold immunochromatography reagents and other point-of-care testing (POCT) Diagnostic reagents and instruments.

Intrinsic Value
23.45 CNY
Fairly Valued
Intrinsic Value
Price
N

See Also

What is Nanjing Vazyme Biotech Co Ltd's Total Liabilities?
Total Liabilities
1.7B CNY

Based on the financial report for Dec 31, 2023, Nanjing Vazyme Biotech Co Ltd's Total Liabilities amounts to 1.7B CNY.

What is Nanjing Vazyme Biotech Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
83%

Over the last year, the Total Liabilities growth was 23%. The average annual Total Liabilities growth rates for Nanjing Vazyme Biotech Co Ltd have been 83% over the past three years , 83% over the past five years .

Back to Top